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CD8+ T cell in®ltration into the epidermis is thought
to be a key event in the pathogenesis of psoriasis. A
quantitative competitive polymerase chain reaction
method was developed to examine the expression of
T cell receptor b chain variable region 2, 3, 6.1-3, 8,
and 13.1 genes in the epidermis of psoriatic lesions.
Paired epidermal samples and peripheral blood
samples from ®ve psoriasis patients were studied.
The results demonstrated the expansion of T cell
receptor b chain variable region 3 (two patients), 8
(two patients), and/or 2 (one patient). Contrary to
previous reports, neither b chain variable region
6.1-3 nor b chain variable region 13.1 subgroups
were expanded in any of the lesions. DNA sequence
analysis revealed dominant T cell clones observed in
all expanded b chain variable region families and
heterogeneous populations and/or small clones
observed in nonexpanded b chain variable region
families. Using CDR3 length analysis to examine the
complete b chain repertoire of the in®ltrating T cells
in the lesional epidermis, we found that approxi-
mately 50% of the T cell receptor b chain variable
region families in each patient's lesion demonstrated
abnormal CDR3 DNA length distribution, indicating
the presence of monoclonal or oligoclonal T cell
expansion. Together, the results show that among
different patients, T cell oligoclonality is not
restricted to a limited number of T cell receptor
b chain variable region families. In an attempt to
identify the pathogenic T cells among the many
expanded T cell clones in the lesions, we compared
T cell receptor expansion in the lesional epidermis
with nonlesional epidermis. Particular T cell receptor
were found to be preferentially expanded in lesional
epidermis and these lesion-speci®c T cell clones may
be most important in the pathogenesis and develop-
ment of psoriatic lesions. Key words: autoimmune
diseases/competitive PCR/T cell repertoire analysis. J
Invest Dermatol 117:1546±1553, 2001
P
soriasis vulgaris, a common in¯ammatory skin disease, is
characterized by abnormal keratinocyte differentiation,
hyperproliferation of keratinocytes, and in®ltration of
in¯ammatory cells (Boehncke et al, 1996; Ortonne,
1996). Although there has been debate over whether
keratinocyte or lymphocyte abnormalities drive the disease,
association with certain HLA class I genotypes (e.g., Cw6) and
recent evidence demonstrating the importance of T lymphocytes in
the pathogenesis of psoriasis implicate a lymphocyte-mediated
etiology (Tiilikainen et al, 1980; Gottlieb et al, 1995a,b; Wrone-
Smith and Nickoloff: 1996). The strongest evidence for a
lymphocyte-mediated pathogenesis comes from clinical studies
using lymphocyte selective therapies, including immunosuppressive
drugs (e.g., cyclosporine A) (Wong et al, 1993; Gottlieb et al,
1995b), bone marrow transplantation (Eedy et al, 1990), and T
lymphocyte speci®c drugs (e.g., anti-CD4 antibodies and inter-
leukin-2-toxin conjugate) (Thivolet and Nicolas, 1994; Gottlieb et
al, 1995a). Treatment with the interleukin-2 toxin drug not only
reversed the T lymphocyte abnormalities, but also reversed other
epidermal abnormalities (e.g., epidermal thickening and keratino-
cyte hyperplasia), implicating a central role for lymphocytes in the
pathogenesis of psoriasis. Moreover, animal models of psoriasis have
succeeded in generating psoriatic skin lesions by injecting activated
blood-derived T lymphocytes into SCID mice with autologous
human-grafted skin (Wrone-Smith and Nickoloff, 1996; Nickoloff
and Wrone-Smith, 1999). Recent ¯ow cytometry analysis has
further characterized the functional phenotype of the intraepider-
mal T cells as CD8+CD3+ GMP-17+ (cytotoxic granule), with a
subpopulation expressing the activation marker CD25+. These cells
were found in lesional psoriatic skin but not in nonlesional skin or
resolving lesion skin, suggesting a functional connection to the
maintenance of psoriatic lesions (Austin et al, 1998). Furthermore,
analysis of the lymphokine pro®les of isolated T cells from psoriasis
patients demonstrated a shift towards production of type I
cytokines, e.g., interleukin-2, tumor necrosis factor-a, and
interferon-g, both in lesional skin and peripheral blood, suggesting
an imbalance in the T cell population, possibly contributing to the
continued activation of T cells in psoriasis (Prinz, 1997; Austin et al,
1999).
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T cells in psoriatic lesions have been reported to show
preferential usage of certain T cell receptor b chain (TCRBV)
families in the in®ltrating T lymphocytes possibly implicating a role
for microbial antigens/superantigens in triggering psoriatic diseases
(Travers et al, 1999; Leung et al, 1995a, b; Skov and Baadsgard,
1995). Polyclonal expansion of BV2 by a streptococcal super-
antigen has been demonstrated in nonlesional skin at the advancing
edge of guttate psoriasis lesions, implicating the streptococcal
pyrogenic exotoxin C as the initiating agent (Leung et al, 1995a).
Conversely, the ®nding of clonal expansions in chronic psoriasis
vulgaris has been used to implicate conventional antigens rather
than superantigens in triggering the psoriasis vulgaris; however,
there is considerable debate concerning the pattern of TCR
subfamilies preferentially expressed in psoriatic lesions. Oligoclonal
expansion of intraepidermal CD8+ lymphocyte expressing BV3 and
BV13.1 has been reported in established plaques of type I (early age
at onset) psoriasis (Chang et al, 1994); however, preferential
expression of other BV have been described in whole dermal/
epidermal preparations, including BV2 and BV6 (Menssen et al,
1995), BV2 and BV5.1 (Lewis et al, 1993). Other studies found no
pattern of expansion in the lesions compared with that in the blood
(Boehncke et al, 1995; Moss et al, 1997). The dif®culties of ®nding
and de®ning the expanded subfamilies in the lesional T cell
populations are probably due to variations among various studies in
polymerase chain reaction (PCR) techniques and tissue examined.
In these studies, analysis of TCR b chain repertoire were best
characterized by studying the T cell in®ltrates in the dermis of early
lesions (Leung et al, 1995a; Norris et al, 1997) and in the epidermis
of established lesions (Chang et al, 1994). With appropriately
selected tissue samples, study of TCRBV usage and the DNA
sequencing of the TCR CDR3 (complementarily determining
region 3) junctional region may facilitate understanding of the role
of the TCR±antigen interaction in the pathogenesis of psoriasis and
further help in developing novel therapies for treatment of this
disease.
In this study, we developed a competitive PCR method to
quantify TCRBV expression in the psoriatic biopsy samples and
examine BV usage independent of PCR primer ef®ciency. The BV
usage and clonality of each BV family was examined using
epidermal tissue separated from biopsies of psoriatic lesions, and the
results compared with peripheral blood from the same patient.
DNA sequencing and CDR3 length analyses were also used to
examine closely the clonality in each T cell BV family. Consistent
with previous reports (Lewis et al, 1993; Chang et al, 1994;
Boehncke et al, 1995; Menssen et al, 1995; Moss et al, 1997), we
observed marked T cell oligoclonality in the epidermis of psoriatic
lesions, but contrary to some reports (Chang et al, 1994; Lewis et al,
1993; Menssen et al, 1995), we observed no preferential use of
speci®c BV (e.g., BV3 or BV13.1) in the ®ve patients examined. In
addition, comparison of TCRBV use in lesional, active lesional
(advancing edge), and perilesional nonlesional psoriatic biopsies,
demonstrated expansions of T cell clones in established and active
lesional epidermis, but not in nearby nonlesional epidermis,
potentially establishing a novel way to identify disease relevant
clones.
MATERIALS AND METHODS
Patient sample processing All six psoriasis patients (Table I), aged
27±70, had recent recurrence of active plaques. None of the patients
were treated with immune suppressive drugs immediately prior to the
time of sampling. Three six millimeter punch biopsies were taken from
the patients' skin, two from independent and physically separated
clinically active lesions (L1 and L2) and one from clinically nonlesional
skin (N). A skin biopsy was also taken from a healthy 50 y old individual
without evidence of any skin disorder. Blood was drawn at time of skin
biopsy, and peripheral blood lymphocytes (PBL) isolated on a Ficoll/
Hypaque gradient and positively selected into CD4+and CD8+
populations by Dynal bead sorting (Dynal, Great Neck, NY). PBL were
also prepared from the blood of a healthy 26 y old individual and used as
the reference in CDR3 length analysis. Skin punch biopsies were soaked
overnight at 4°C in dispase buffer and the epidermis peeled off and
immediately immersed into ``Ultraspec'' RNA isolation reagents
(Biotecx, Inc., Houston, TX) followed by homogenization. RNA
puri®cation was performed according to the manufacturer's protocol.
cDNA was synthesized by AMV reverse transcriptase using an oligo dT
primer (Promega, Madison, WI).
TCRBV primers TCRBV-speci®c primers were chosen from
published studies and primers with the highest ef®ciency were used in
this study (BV 1, 3, 4, 5.1, 6.1±3, 6.7, 7, 8, 9, 13.1, 13.2, 14, 18, 20,
23, and 24 from Choi et al, 1989; BV 2, 11, 15, 21, and 22 from
Maslanka et al, 1995; BV 12, 16, and 17 from Clontech, Palo Alto, CA).
T cell receptor b chain constant region (TCRBC) was used as an
internal control using the forward BC28 (5¢CGAGGTCGCTGTGT-
TTGAGC) and reverse BC238 (5¢GCGGCTGCTCAGGCAGTATC)
oligonucleotides. Fluorescein-labeled reverse primers were used in the
quantitative competitive PCR (QC-PCR) (reverse BC83F/5¢TGGCCT-
TTTGGGTGTGGGAG) and CDR3 length analysis (reverse BC66F;
Maslanka et al, 1995). An unlabeled reverse BC83 primer was used in
the PCR cloning for DNA sequence analysis. Oligo primers and
¯uorescein-labeled primers were synthesized by BioServe
Biotechnologies (Laurel, MD).
Construction of competitors for QC-PCR Competitors (illustrated
in Fig 1A) used for this study were constructed by series of
recombination of TCR b chain constant region (BC) and the polylinker
from pGEM7. The resulting plasmid, pGEM7-BC+, consisted of a 40
base pair polylinker at the BglII site in TCRBC coding region. The
competitor, BC+, was prepared by amplifying pGEM7-BC+ with
primers derived from the conserved regions between BC1 and BC2. The
V±DJ±C sequences from individual TCRBV families were added 5¢ to
the polylinker of pGEM7-BC+ at the BglII site in TCRBC coding
region and resulted in competitor for each BV families (named BVX+).
Competitors BV2+, BV3+, BV6.1±3+, BV8+, and BV13.1+ were
constructed for this study, and each have approximately a 40 bp increase
in size relative to their wild-type sequence (ranged from 200 to 250 bp)
(Fig 1A). Competitors were PCR ampli®ed, gel puri®ed and quanti®ed
by ultraviolet absorbency at A260. Competitors were serially diluted
approximately 3-fold to concentrations as low as 0.0003 pg per ml.
QC-PCR A ®xed amount of cDNA (diluted if necessary) was added
to a set of tubes with various dilutions of the competitors. The PCR
mix consisted of a total volume of 20 ml: 1 3 PCR buffer (10 mM
Tris±HCl, 50 mM KCl, 1.5 mM MgCl2, 0.001% gelatin), 0.2 mM
deoxyribonucleoside triphosphate, 0.6 mM of each primers (3¢ primers
were end labeled with ¯uorescein; 3¢-BC83F for all BV PCR and 3¢-
BC238F for BC PCR), and 0.75 U Taq DNA polymerase (Promega).
All QC-PCR reactions were run at the following conditions for 35
cycles: 94°C for 30 s, 56°C for 1 min, 72°C for 1 min; followed by an
extension at 72°C for 6 min. A FluorImager/ImageQuaNT (Molecular
Dynamic, Sunnyvale, CA) quanti®ed the PCR products separated on
2.5% Metaphor agarose (FMC, Rockland, ME) in 1 3 tris-borate-
EDTA buffer (TBE). The signals were plotted on a log±log scale of
competitor concentration (pg per ml) vs the ratio (competitor/target) of
¯uorescent intensity, and the target cDNA concentration was obtained at
the ratio of 1 : 1 (i.e., log ratio = 0). An example of the TCRBV QC-
PCR and its calculation is shown in Fig 1(B,C). As shown in Fig 1B,
the signal of the target DNA increased as the competitor concentration
decreased. Unlike the PCR products of the constant region (BC), the
heterogeneous population in the BV PCR products will result in a
Table I. Psoriasis patient information
PP
no. Age Sex
Duration of
psoriasis
Biopsy site
(label)a
1 27 M 2 y Back (L1)
2 70 M 20 y Thigh (L1, L2, N)
3 70 F Since childhood Thigh (L1, L2, N)
4 45 M Since childhood Knee (L1), back (L2, N)
5 40 M 18 y Back (L1, L2, N)
6 50 M 3 mo Back (L, L/N, N)
aL1 and L2 represent lesions taken from separated plaques. N was the biopsy
taken from normal nonlesional skin. In PP6, L was the biopsy taken from the
center of the lesion, L/N was from the edge of the same lesion, and N was from
the perilesional uninvolved skin.
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cluster of bands as shown in the right panel of Fig 1B. The percentage
of a particular BV chain was calculated by dividing the target DNA
concentration of the BV with the concentration of the BC in the same
cDNA preparation (Fig 1C). QC-PCR was also used to quantify
TCRBC message, which was used as an internal control and/or a
measure of total T cell speci®c message in each cDNA preparation for
subsequent DNA sequencing and CDR3 length analyses.
TCR b chain sequence analysis The cDNA template in each 20 ml
PCR reaction was adjusted to an amount equivalent to 0.1 pg TCRBC
message, the amount we previously determined to be suf®cient to
minimize PCR skewing. Taq polymerase (Promega) was used to amplify
the CDR3 regions by the reverse BC83 primer paired with individual
BV primers previously described. The conditions for PCR were similar
to that used in QC-PCR except that fewer cycles (30 cycles) were used
to reduce skewing due to extensive ampli®cation. PCR products
containing the CDR3 regions were gel-puri®ed and cloned into the
pCRII vector using the TA cloning system (Invitrogen, Carlsbad, CA).
The CDR3 sequences of individual clones were determined by an ABI
automatic sequencer (PE Biosystems, Norwalk, CT) using the M13
forward primer site in the pCRII vector.
CDR3 length analysis CDR3 length analysis is a PCR-based assay
that analyzes the length spectrum of TCRB chain VDJ region in a given
T cell population (Maslanka et al, 1995). cDNA equivalent to 0.05 pg
TCRBC message was ampli®ed for 35 cycles with ¯uorescein-labeled
BC66 reverse primer paired with 24 BV speci®c forward primers using
cloned pfu DNA polymerase (Stratagene, La Jolla, CA). Preliminary
experiments demonstrated that cDNA at concentrations as low as
0.03 pg of TCRBC message in a 20 ml PCR reaction was able to
generate consistent CDR3 pattern after 35 cycles of PCR. In some
patients, two pairs of TCRBV primers were used in each reaction due to
limited cDNA obtained from the epidermis. PCR products were mixed
3 : 1 with formamide/dye, denatured at 80°C for 5 min and separated
on a vertical 6% polyacrylamide gel/urea/1 3 TBE. Gels were scanned
with a FluorImager and individual bands analyzed using the area
quantitation program provided by the ImageQuaNT software (Molecular
Dynamic, Sunnyvale, CA).
RESULTS
Quantitative analysis of TCRBV expression in psoriatic
lesions We developed a QC-PCR to investigate the expression
of certain TCRBV families in the epidermis from biopsies of
psoriatic skin lesions. QC-PCR quanti®es DNA relative to a DNA
standard (competitor) added to the PCR reaction therefore it
avoids the variations often seen in semiquantitative PCR due to the
differences in the primer ef®ciency and the PCR conditions. QC-
PCR of TCRBC (used to reveal total TCR message) and the four
TCRBV (BV2, 3, 6.1±3, and 13.1) previously suggested to be
overexpressed in lesions (Chang et al, 1994; Menssen et al, 1995) as
well as TCRBV8 (TCRBV control) were used to analyze cDNA
from lesional epidermis and CD8+ PBL from ®ve psoriasis patients
(PP1±PP5, Table I). Expansion of a TCRBV family in a lesion
was de®ned as a greater than 2-fold increase compared with CD8+
PBL of the same patient. Of the ®ve patients examined, a TCRBV
expansion was only observed in PP2 (BV3 and BV8) and PP3
(BV2, BV3, and BV8) (Table II). Contrary to previous reports
(Chang et al, 1994; Menssen et al, 1995), consistently increased
expression of TCRBV 2, 3, 6.1±3, or 13.1 was not observed in the
®ve patients examined. TCRBV analysis of an independent lesion
(lesion 2) in PP3, PP4, and PP5 gave comparable results with lesion
Figure 1. Quantitative competitive PCR for T cell receptor
chain. (A) Diagram of the construction of competitors used for
quantitative competitive PCR analysis of TCRBV expression. Details of
each TCRBV competitor construction are described in Materials and
Methods. Arrows indicate the position of PCR primers used to amplify the
competitor fragment. (B) Quantitative competitive PCR for TCRBC
and TCRBV2 in the lesion 2 of psoriasis patient 3. A ®xed amount of
cDNA was added to compete with dilutions of the competitors. At least
four competitor dilutions were used for each TCRBV or BC
determination. PCR products were separated on a 2.5% agarose gel and
the intensity of ¯uorescence quanti®ed. (C) Logarithmic plots of
quantitative competitive PCR titration and calculation of TCRBV
percentage. The concentration of the target DNA in the sample was
obtained when the ratio of competitor/target equals 1.
Table II. Analysis of TCRBV expression by competitive PCR
BV
% BV expression in skin lesion/PBLa
PP1 PP2 PP3 PP4 PP5
Lesion 1 Lesion 1 Lesion 1 Lesion 2 Lesion 1 Lesion 2 Lesion 1 Lesion 2
2 7.7/5.4 5.5/4.4 50.7/3.4 33.1/3.4 3.3/3.3 2.5/3.3 9.4/7.7 10.2/7.7
3 3.5/1.9 20.4/8.4 32.4/4.3 71.1/4.3 3.1/0.9 1.5/0.9 4.9/15.4 7.4/15.4
6.1±3 1.0/1.5 4.2/23 4.4/5.3 3.1/5.3 12.1/15.6 7.0/15.6 1.9/16.5 2.1/16.5
8 5.7/4.4 88.1/1.0 9.0/10.9 25.5/10.9 2.4/5.6 2.8/5.6 8.0/12.2 7.3/12.2
13.1 3.5/5.5 3.0/3.4 4.1/16.4 3.1/16.4 2.6/16 2.5/1.6 6.8/7.8 6.4/7.8
aPercentage of each TCRBV was calculated as illustrated in Fig 1. Individual TCRBV in the T cells of the lesional epidermis was compared with that in the CD8+ PBL
of the same patient. The underlined values represent TCRBV expanded more than 2-fold in the lesion compared with CD8+ PBL. Lesions 1 and 2 were sampled from
separated lesions at the same time.
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1, with the exception of PP3, in which a BV8 expansion was only
observed in lesion 2 (Table II).
Oligoclonality in the expanded TCRBV families To
understand better the TCR repertoire in the expanded and
nonexpanded TCRBV, the CDR3 regions of TCRBV3 and
BV8 in the lesional T cells from PP1 to PP5 were analyzed. For
each patient, approximately 30 PCR-ampli®ed TCRBV DNA
were sequenced. Dominant T cell clones (i.e., greater than 50% of a
TCRBV subset with identical CDR3 sequence) were observed in
most of the expanded BV identi®ed previously by quantitative
competitive PCR (Table II). For example, the BV3 in lesion 1 of
PP3 had expanded to 32.4% compared with only 4.3% of BV3 in
the CD8+ PBL (Table II). Sequence analysis of the TCRBV3
family in this lesion showed a dominant clone (CDR3 sequence:
CASSPQGTALNVYFG with VDJ junctional sequence
underlined, Table III), which occurred in 17 of 27 clones
sequenced. In contrast, TCRBV families with expansion ratio
less than 2 showed a heterogeneous population or only small clones
that occupied less than 25% of the total clones sequenced
(Table III). Most of the dominant clones originated from the
same T cell clone as evidenced by identical CDR3 DNA
sequences. Interestingly, a small BV8 clone (four of 26 clones) in
PP5 with a CDR3 region amino acid sequence of
CASSPGGETQYFG originated from three different DNA
sequences with 2 or 3 base pair differences, suggestive of antigen
selection for this TCR in this patient; however, it is not clear
whether this clone has disease relevance.
Limited CDR3 sequence analyses of T cells from the second
lesion, the nonlesional skin, the CD4+ PBL and the CD8+ PBL of
PP2 and PP3 was also performed. T cell clones expanded in the ®rst
lesion were expanded in the second lesion to a similar percentage,
expanded to a lesser percentage in the nonlesional skin and the
CD8+ PBL, and rarely observed in the CD4+ PBL (data not
shown).
CDR3 sequence analysis of BV3 and BV8 from the epidermis of
a 50 y old healthy individual demonstrated the presence of small
clones in both BV, but not the dominant clones observed in the
psoriasis patients (Table IV). The signi®cance of these small clones
is unclear, however, it suggests the expansion of nonpathogenic T
cell clones in normal healthy epidermis, indicating that clonal
expansion does not necessarily signify disease relevance.
Clonal expansion of lesional T cell but no preferential
patterns among patients As clonal expansions were frequent in
Table III. CDR3 sequence analysis of TCR BV3 and BV8 in psoriasis patients
PP BV
Expansion
ratioa
Sequence analysis
Repeat/total V-D-J junction sequence BJ
1 BV3 1.84 4/27
3/27
2/27, 2/27
CASS
CA
LGQGAW
TSLWAEG
ETQYFG
YGYTFG
2.5
1.2
BV8 1.30 3/32
2/32, 2/32, 2/32
CASS DRGHG NQPQHFG 1.5
2 BV3 2.4 20/24 CASS QRGGYH EQYFG 2.7
BV8 88.1 25/26 CASS LER NTEAFFG 1.1
3 BV3 7.53 17/27
5/27
3/27
CASS
CAS
CASS
PQGTALNV
RLRLTD
RGPSGTVPL
YFG
EQYFG
SGNTIYFG
2.7
2.7
1.3
BV8 2.34 11/23 CASS LGRA YGYTFG 1.2
4 BV3 3.44b 5/17
3/17
2/17
CASS
CASS
LNIL
PGTA
NTEAFFG
YEQYFG
1.1
2.7
BV8 0.43 8/26
3/26
2/26
CASS
CASS
LGLT
LYV
YEQYFG
EQFFG
2.7
2.1
5 BV3 0.32 6/26
2/26, 2/26, 2/26
CASS RSGTGP SYEQYFG 2.7
BV8 0.66 4/26c
2/26, 2/26, 2/26
CASS PGG ETQYFG 2.5
aRatio of percentage TCRBV expressed in the lesion to that in CD8+ PBL of the same patient. A ratio over two-fold is considered an overexpression.
bThe TCRBV percent values are less than 5% in both PBL and the lesion.
cThree different nucleotide sequences (T cell clones) were noted to encode this CDR3 amino acid sequences.
Table IV. CDR3 sequence analysis of TCR BV3 and BV8 in the epidermis of a healthy individual
BV Repeat/total
CDR3 amino acid sequence
BJV-D-J junction
BV 3 3/21 CASS PSRTYFVGKEL YEQYFG 2.7
3/21 CASS YRVGE SYEQYFG 2.7
BV 8 4/24 CASS PGDRG SPLHFG 1.6
4/24 CASS LGDRLAVR SYEQYFG 2.7
3/24
2/24, 2/24
2/24, 2/24
CASS LVGP DTQYFG 2.3
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the set of TCRBV examined by sequence analysis, CDR3 DNA
length analysis was developed and used to examine TCRBV usage
in broader range of TCRBV families. Twenty-four different
TCRBV speci®c primers were paired with a ¯uorescein-labeled
TCRBC primer for the PCR CDR3 analysis using a 20 ml reaction
containing cDNA equivalent to 0.05 pg of TCRBC message. The
heterogeneous CDR3 DNA fragments were resolved by
sequencing gel electrophoresis. A normal CDR3 DNA length
distribution follows a Gaussian distribution with the greatest
intensity in the central bands with gradual decreasing intensity in
the ¯anking bands (Maslanka et al, 1995). An abnormal CDR3
spectrum shows a skewing of bands from the normal distribution
resulting from the selective expansion of T cells expressing a
particular CDR3 length (Maslanka et al, 1995). Figure 2 shows
a representative CDR3 length spectrum of CD8+ PBL from a
healthy control, as well as CD8+ PBL and psoriatic lesion from
PP2. Figure 3 summarizes the CDR3 analyses of PP2 to PP5 and a
healthy control. The CDR3 length spectra were analyzed by
ImageQuaNT as described in Materials and Methods. Abnormality of
a CDR3 spectrum was expressed as the total increase of all the
abnormal peaks as compared with its normal Gaussian background
taken from the CD4+ PBL of a healthy young individual. As shown
in Fig 3 and its legend, the degree of abnormality was categorized
into four groups, normal distribution, and abnormal peaks occupied
by < 25%, 25±50%, or > 50% of the population. Three different
patterns of CDR3 length distribution in CD8+ PBL and in psoriatic
lesions were observed: (i) T cell clonal expansion (i.e., abnormal
distribution) prominent in the CD8+ PBL but less in the lesional T
cells (e.g., PP2/BV5.1); (ii) T cell clonal expansion in both the
CD8+ PBL and lesional T cells (however, the expanded clones are
not the same in these samples, e.g., PP2/BV3); and (iii) T cell
clonal expansion in the lesional T cells but not in the CD8+ PBL
(e.g., PP2/BV20). In the older patients (PP2 and PP3), oligoclonal
T cells were found in the psoriatic lesions, as well as in the CD8+
PBL. In younger patients (PP4 and PP5), T cell clonal expansion
was found with higher frequency in the lesion than in the CD8+
PBL. In a young healthy control, one-third of the BV in the CD8+
PBL had moderate abnormal CDR3 distribution (25±50%
abnormal) compared with zero abnormal spectra in the CD4+
PBL. In addition, CDR3 length analysis on selected BV in lesion 2
samples revealed similar CDR3 spectra as lesion 1, but different
from the CDR3 spectra of CD4+ or CD8+ PBL (data not shown).
Overall, clonal T cell expression in the psoriatic lesion was
observed in every patient studied; however, expansions exhibited
no preferential usage of a particular TCRBV among patients. Thus,
the pattern of clonal expansion was different for each patient.
QC-PCR, CDR3 sequence, and length analyses provided
comparable and consistent results CDR3 DNA sequence and
CDR3 length analyses both identi®ed large clonal expansions in
PP2/BV3 and PP2/BV8 (compare Table III with Figs 2 and 3).
DNA sequencing of the band with the strongest intensity excised
from the CDR3 spectrum of PP2/BV8 lesion 1 revealed the
identical dominant sequence (CASSLERNTEAFFG) found using
CDR3 sequence analysis of the same lesion. Comparison of the
results of QC-PCR in Table II with the CDR3 length analysis in
Fig 3 demonstrated monoclonality or oligoclonality in all the
expanded TCRBV families. In addition, nonexpanded TCRBV
families also exhibited clonality (e.g., PP5 BV3 and BV8,
Table III). Therefore, simply examining the expanded BV
families may be insuf®cient to identify all dominant T cell clones
in a psoriatic lesion.
Identi®cation of expanded clones in psoriatic lesional but
not in nearby nonlesional skin In an attempt to identify
disease-relevant T cell clones among the many expanded clones, we
examined skin biopsies at different disease stages in a recent and
active psoriasis patient (PP6). Sample L was taken from the center
of a small recent lesion, sample L/N from the advancing edge of the
lesion (but still within the lesion), and sample N from the
perilesional nonlesional skin. All three sample sites were taken from
the back of PP6 and were less than 2 cm apart. CDR3 length
analysis was used to examine the TCRBV repertoire in the
epidermis of these skin biopsies, as well as in the CD4+ and CD8+
PBL (Fig 4). Only 10 of the 24 TCRBV families were studied due
to a limited T cell message in the nonlesional epidermal samples.
The majority of CD4+ or CD8+ PBL displayed normal CDR3
length distribution implicating a heterogeneous repertoire. In
contrast, skin samples displayed different patterns of CDR3 length.
Some TCRBV families (BV9 and 14) showed normal CDR3
length distribution in all three skin samples. Other TCRBV
(BV5.1, 6.1-3, and 6.7) showed evidence of the same clonal
expansion in lesional (L), advancing edge (L/N), and uninvolved
skin (N). Interestingly, two TCRBV families (BV2 and 8)
demonstrated clonal expansion only in the lesional epidermis (L
and L/N), but not in the nonlesional epidermis (N) (Fig 4).
Figure 3. Summary of CDR3 length analysis of psoriasis patients
2±5 and a healthy control. The CDR3 spectra were analyzed by
ImageQuaNT and compared with the Gaussian distributions obtained
from the CD4+ PBL of a healthy individual. Peaks that are 10% above
their corresponding peaks in a normal Gaussian background were
considered abnormal. The total percentage of the abnormal peaks in each
BV family were grouped into < 25%, 25±50%, and > 50% (symbols for
each group shown in ®gure). The white square corresponds to a normal
Gaussian distribution. Typical histograms of each category are illustrated
under the symbols.
Figure 2. CDR3 length analysis of psoriasis patient 2 and a
healthy control. The cDNA from CD8+ PBL of a healthy control (a)
and CD8+ PBL of psoriasis patient 2 (b) as well as from the lesions of
the patient (c) were ampli®ed with 24 TCRBV speci®c primers paired
with the ¯uorescein-labeled TCRBC primer. The ampli®ed CDR3
variable regions were then separated by a 6% polyacrylamide sequencing
gel and scanned with a FluorImager Two TCRBV were analyzed in
each lane to conserve cDNA. The BV families were indicated above
each set of samples with upper and lower number representing the
spectra at top and bottom, respectively.
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Detailed analysis of the TCRBV8 CDR3 regions from L, L/N, and
N demonstrated a dramatic increase of CDR3 length of 10 amino
acids in L and L/N but not in N. Sequence analysis of the BV8
CDR3 regions from these different biopsies con®rmed the
preferential clonal expansion of a clone with this length bearing
the CDR3 junctional sequence CASRRRVNTEAFFG
(Table V).
DISCUSSION
Recent studies indicate the importance of T lymphocytes in
psoriasis; however, their role in the pathogenesis of this disease
remains unclear. Norris et al (1997) has proposed that a systemic
nonspeci®c activation of T cells (most likely, CD4+ cells) occurs in
the very early stage of psoriasis. After the initial nonspeci®c
stimulation of lymphocytes, local events such as the release of
cytokines, costimulation, and cell traf®cking further recruit
lymphocytes (especially CD8+ T cells) into the epidermis, resulting
in plaque psoriasis. The initial nonspeci®c CD4+ cells expansion in
both dermis and epidermis is supported by the observation of
nonspeci®c activation of BV2 in guttate psoriasis, an acute form of
psoriasis (Leung et al, 1995a). Nickoloff and Wrone-Smith (1999)
also showed that injection of autologous CD4+ but not CD8+ T
cells can induce psoriatic lesions in the symptomless skin grafted on
SCID mice. The importance of CD8+ T cells in maintaining
psoriasis is supported by CD8+ T cells dominating the epidermal
lymphocyte in®ltrate in established lesions (Vallet et al, 1994 and
Gottlieb et al, 1995b), and the association of psoriasis with certain
class I major histocompatibility complex molecules (especially
HLA-Cw6) (Tiilikainen et al, 1980). The initial stage of psoriasis is
hard to de®ne except in guttate psoriasis, therefore, we focused on
studying the epidermal in®ltrating CD8+ T cells in established
psoriatic lesions of relatively recent onset.
This study analyzed the T cell repertoire in the epidermis of
psoriatic lesions using quantitative competitive PCR, CDR3 length
spectra typing and CDR3 region sequencing analyses. Through
these analyses, we found oligoclonal T cell expansion within
individual patients, but no consistent pattern of TCRBV over-
expression compared with blood CD8+ T cells in the six patients
examined. These results are consistent with some previous reports
(Boehncke et al, 1995; Moss et al, 1997), and inconsistent with
others (Lewis et al, 1993; Chang et al, 1994; Menssen et al, 1995).
We believed the discrepancy of expression levels of BV T cells in
various studies is probably due to: (i) differences in skin sample
preparation; (ii) PCR analysis methods; and/or (iii) differences in
disease stages. Most of the previous studies examined the T cells in
full thickness skin biopsies compared with unsorted PBL (Menssen
et al, 1995; Moss et al, 1997; Vekony et al, 1997) and the result
varied. Menssen et al (1995) reported clonal expansion of TCRBV2
and BV6 families in established lesions in the majority of their
patients. In contrast, Vekony et al (1997) studying ``early'' lesions
found only a slightly increased use of these two BV families in two
of their 10 psoriasis patients. Moss et al (1997) observed
overexpression of certain BV families in the lesional and
nonlesional skin of the psoriasis patients, but observed no BV
consistently overexpressed in a simple majority of their patients.
Without separating the dermis and epidermis, the analyses in these
studies include both dermal and epidermal T cells rather than a
strict analysis of the in®ltrating epidermal CD8+ T cells. Chang et al
(1994) using puri®ed CD4+ and CD8+ T cell populations in
0.4 mm shave biopsies observed consistent clonal expansion of
TCRBV3 and BV13.1 in CD8+ T cells, but not in CD4+ T cells
(Chang et al, 1994). Owing to the irregular hyperplasia and
epidermal thinning of psoriatic skin (Pinkus and Mehregan, 1966),
however, these shave biopsies are also likely to contain contam-
inating dermal T cells. To minimize contamination from dermal T
cells, in this study, the epidermal layer was dissociating from the
dermis by dispase treatment of the skin punch biopsy. Using a
quantitative PCR to compare the relative amount of CD4+ and
CD8+ T cell messages, we observed higher levels of CD8+ T cell
mRNA in punch biopsies/dispase-treated epidermal samples
compared with shave biopsies skin samples, which is consistent
with better isolation of epidermal T cells (data not shown).
The PCR analyses are powerful tools to quantify trace amounts
of messages in a limited epidermal preparation; however, care has to
Table V. Summary of TCR BV8 sequences in lesions at different disease stages in psoriasis patient PP6a
BJ
CDR3 sequence Number of sequence
BV NBDN BJ L L/N N
1.1 CAS RRRV NTEAFFG 20 15 2
1.4 CASS LGRRIQVG EKLFFG 0 0 4
1.6 CASS FGRD NSPLHFG 1 0 3
1.6 CASS SWGS SYNSPLHFG 0 0 2
2.1 CASS FRGG EQFFG 0 0 4
2.1 CAS LRGG SYNEQFFG 1 0 3
2.1 CASS LRIAGGPA QFFG 5 1 2
2.2 CASS LRGGGRL GELFFG 0 1 2
2.3 CASS PRLAG STDTQYFG 3 5 0
2.3 CASS QPNSRG TQYFG 0 0 2
Non-repeated single sequence 5 9 14
Total 35 31 38
aL was taken from the center of the lesion; L/N was taken from the edge of the same lesion; N was from a perilesional uninvolved skin.
Figure 4. CDR3 length analysis of psoriasis patient 6 (PP6).
cDNA from CD4+ PBL, CD8+ PBL, and the epidermis of lesion center
(L), lesion margin (L/N) and nonlesional skin (N) were ampli®ed with
TCRBV-BC primer pairs and separated by 6% sequencing gels. The gels
were analyzed as described in the Materials and Methods.
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be taken when using PCR for quanti®cation, particularly on the
amount of template added and the primer ef®ciency. T cell message
is limited in the epidermal skin samples especially in the nonlesional
epidermis. In this study, we have optimized the epidermal
preparation, designed, and applied a quantitative competitive
PCR to quantify the TCR BC as the indicator of total T cell
message in a sample. By predetermining the minimum TCR
cDNA template amount, we are able to control the total TCR
cDNA added to each PCR reaction and thereby minimize the
possibility of PCR ampli®cation skewing due to limited TCR
template (see Materials and Methods). In addition, we also developed
and applied the QC-PCR to quantify individual TCR BV
expression level in samples. QC-PCR includes an internal standard
(a competitor) for each TCR BV primer pair; therefore, the result
is quanti®ed based on the competitor and is independent of primer
ef®ciency. All of the previous reports have used the semiquanti-
tative PCR to analyze TCR BV expression (Lewis et al, 1993;
Chang et al, 1994; Boehncke et al, 1995; Menssen et al, 1995; Moss
et al, 1997). The result from semiquantitative PCR varies with the
primer ef®ciency, where more ef®cient TCR BV primers will play
up its percentage, and less ef®cient primers will result in lower BV
expression level.
Despite the contradictions on which TCRBV families are
overexpressed, this study and all previous TCR repertoire analyses
of psoriatic lesions have noted the expression of T cell clones. For
comparison, we further analyzed and/or sequenced selected TCR
BV families in CD8+ PBL, psoriasis nonlesional skin, and normal
healthy epidermis. Owing to the limited T cell message in an
epidermal preparation, sequencing of CDR3 junction region is
normally limited to a few selected BV families that have shown
expansion. In this study, we have successfully developed the CDR3
length analysis for epidermal T cells, which allows us to view the
distribution of T cell repertoire by the full panel of BV families with
a minimum amount of samples. With the analysis of 24 TCR BV
families by the CDR3 length analysis, we are able to demonstrate
that T cell clonal expression was found in many BV families in all
samples analyzed (Figs 2 and 3). Clonal T cells were observed in
the CD8+ PBL as well as in the skin biopsy from a healthy adult
(Table IV), although they were less frequent and less dramatic than
samples from the lesional epidermis. The result is consistent with a
recent study showing restricted TCR repertoires in healthy adult's
skin (Menssen et al, 2000). Studies have shown that oligoclonality
or monoclonality of CD8+ T cells increases as people age
(Batliwalla et al, 1996). Individuals with a mean age of 65 y have
an average of 3.5 dominant CD8+ T cell clones per individual
compared with 2.2 clones in individuals with a mean age of 38 y.
Ricalton et al (1998) also reported the age-dependent expansion of
CD8+ T cells in the PBL of healthy individuals, with 0% expansion
for 9 mo olds, 13.3% for 20±30 y olds, 20.7% for 35±50 y olds, and
33.4% for 65±85 y olds. Consistent with these studies, we also
observed tremendous overexpression of lesional T cells in the two
older patients (PP2 and PP3), with at least two expanded BV
among ®ve TCRBV examined, but not in younger patients
(Table II). Clonality was even more prevalent when using CDR3
length analysis and CDR3 sequence analysis to examine the CDR3
region of individual BV family of the lesional T cells and CD8+
PBL. Clonality was observed in both expanded and nonexpanded
TCRBV families in old and young patients with more clones
observed in the older patients (Table III, Fig 3). As a result, clonal
expansion of CD8+ T cells observed in this study, as well as the
other studies, may be in¯uenced by the age of the patient through
nonspeci®c migration of T cell clones into the skin and/or clonal
selection by skin-speci®c antigens and foreign antigens/super-
antigens due to infections.
Comparison of TCR b chain CDR3 junctional sequences
between individual patients revealed little similarity; however,
sequence similarity to CDR3 junctional sequences reported in
previous studies (Chang et al, 1994; Menssen et al, 1995; Prinz et al,
1999) were identi®ed. A small clone found in PP4 BV3
(CASSLNILNTEAFFG) is highly homologous to a clone identi®ed
by Chang et al (1994) (CASSLNSLNTEAFFG). Both clones have
the same CDR3 junctional length and use BV3 and BJ1.1. A
lesion-speci®c clone of PP6 (CASSPRLAGSTDTQYFG,
Table V) consists of a CDR3 motif (GLAG) identi®ed in several
psoriasis patients in another study (Prinz et al, 1999). Another small
clone found in the lesional T cells of PP5 BV8
(CASSPGGETQYFG) is homologous to a clone
(CASSPGGGNEQFFG) reported in the study of Menssen et al
(1995). The identi®cation of similar CDR3 junctional sequences
from different patients may indicate the presence of similar T cell
clones in different patients recognizing related antigens that may be
important in the pathogenesis of psoriasis. Interestingly, this BV8
clone from PP5 appears to have originated from three different
nucleotide sequences (data not shown), suggesting the selection of
different T cell clones with a common antigen present in this
psoriatic lesion; however, a similar clone was not observed in other
patients.
With our consistent observation of TCR clonality in lesional
skin, nonlesional skin, and blood PBL from patients as well as
healthy controls, we strongly believe that clones are common as
people aged (especially in CD8+ T cells); therefore, most of the
clones identi®ed are not psoriasis related. In order to identify
disease-related T cells among many clones identi®ed, we further
analyzed a series of biopsies (center of lesion, edge of lesion,
nonlesional) taken from an active psoriatic patient (PP6). In this
patient, the clonal expression of BV3 and BV8 in the lesional
biopsies, but not in the nonlesional skin, was dramatic, possibly
indicating a role for these differentially expressed T cell clones in
the development and maintenance of established psoriasis plaques.
Furthermore, low-level expression of these clones in the nonle-
sional skin is consistent with nonlesional skin being predisposed for
active disease. Further analysis is necessary to determine whether
this differential overexpression of T cell clones is consistently
observed in other patients, and whether this comparison may prove
useful as a method for identifying disease-relevant T cell clones.
In conclusion, we report here that epidermal T cell clones
expanded in psoriasis patients were not unique in the lesional skin.
Using molecular methods, we have been able to detect the presence
of clones in lesional and nonlesional psoriatic lesions, as well as
epidermal skin samples taken from healthy individuals. Dominant T
cell clones were found in some psoriatic patients, but not in all
patients and T cell oligoclonality was not restricted to speci®c
TCRBV families as was previously reported (Chang et al, 1994;
Menssen et al, 1995; Vekony et al, 1997). By comparing the CDR3
length distribution in lesional and nonlesional skins, however, we
have identi®ed clones that are speci®c to the lesions, suggesting a
role for these T cells in the pathogenesis of the disease. Further
characterization of these psoriasis-speci®c T cell clones and the
corresponding antigens may help to understand the mechanism(s)
that trigger psoriasis and the role of T cells in perpetuating the
disease.
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